G La Rocca, G Del Frate, P Delvino… - Clin Exp …, 2022 - clinexprheumatol.org
Systemic vasculitis are rare heterogeneous disorders potentially involving any organ and system with a relevant burden of mortality and comorbidity. As in the previous annual …
Landscape dynamics are a consequence of population growth, which can degrade river ecosystem services. Since various countries approved the millennium ecosystem …
ME Wechsler, B Hellmich, MC Cid, D Jayne… - Journal of Allergy and …, 2023 - Elsevier
Hypereosinophilic syndrome (HES) and eosinophilic granulomatosis with polyangiitis (EGPA) are rare systemic inflammatory disorders with overlapping symptoms, elevated …
A Villa-Forte - Postgraduate Medicine, 2023 - Taylor & Francis
This review aims to describe the epidemiology, pathogenesis, clinical manifestations, diagnosis, treatment, and prognosis of eosinophilic granulomatosis with polyangiitis (EGPA) …
Eosinophilic granulomatosis with polyangiitis (EGPA) is a systemic vasculitis characterized by the presence of asthma associated with eosinophilia, eosinophilic infiltration of different …
DJ Jackson, P Akuthota, R Andradas… - Advances in …, 2022 - Springer
Eosinophil-associated diseases (EADs) are a range of heterogeneous conditions in which eosinophils are believed to play a critical pathological role. EADs include common illnesses …
A Brailean, J Kwiatek, D Kielar, R Katial… - Allergy, Asthma & …, 2023 - ncbi.nlm.nih.gov
Purpose The epidemiology of eosinophil-associated diseases (EADs) is not yet fully understood. While some studies have been conducted on stand-alone eosinophilic …
K Sada, T Suzuki, S Joksaite, S Ju, J Logie… - Modern …, 2024 - academic.oup.com
Objectives We report the prevalence of eosinophilic granulomatosis with polyangiitis (EGPA) and describe oral corticosteroid (OCS) use and disease burden before and after the …
J Silver, A Deb, E Packnett, D McMorrow… - JCR: Journal of …, 2023 - journals.lww.com
Methods This was a database study (GSK study ID: 214156) of US patients (≥ 12 years old) with EGPA and≥ 1 mepolizumab claim (index date) identified from the Merative MarketScan …